Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Ionis Pharmaceuticals, Inc. (IONS:NASDAQ), powered by AI.
Ionis Pharmaceuticals, Inc. is currently trading at $73.09. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Ionis Pharmaceuticals, Inc. on Alpha Lenz.
Ionis Pharmaceuticals, Inc.'s P/E ratio is -30.7.
“Ionis Pharmaceuticals, Inc. trades at a P/E of -30.7 (undervalued) with modest ROE of -70.8%. 3Y revenue CAGR of 17.1% highlights clear growth momentum.”
Ask for details →Ionis Pharmaceuticals, Inc. is a biotechnology company that specializes in the discovery and development of human therapeutic drugs through the use of antisense technology. Founded in 1989 and headquartered in Carlsbad, California, Ionis is recognized for pioneering precision medicines that target RNA to modulate gene expression, addressing a variety of unmet medical needs. The company’s drug development pipeline spans several therapeutic areas, with a focus on severe and rare diseases, neurological disorders, and cardiovascular conditions. Notable for its significant investment in research and development, Ionis’s approach allows for the creation of novel therapies that might not be achievable through traditional pharmaceutical methods. In the broader financial market, Ionis Pharmaceuticals plays a key role within the health technology sector, representing innovative advancements in biotechnology and contributing to the progress of genomics-driven medicine. With a workforce of over 1,000 employees, Ionis continues to impact the healthcare landscape by advancing new treatment options for patients globally.
“Ionis Pharmaceuticals, Inc. trades at a P/E of -30.7 (undervalued) with modest ROE of -70.8%. 3Y revenue CAGR of 17.1% highlights clear growth momentum.”
Ask for details →Ionis Pharmaceuticals, Inc. (ticker: IONS) is a company listed on NASDAQ in the Healthcare sector (Biotechnology). It has approximately 1,069 employees. Market cap is $11.7B.
The current price is $73.09 with a P/E ratio of -30.66x and P/B of 23.91x.
ROE is -70.80% and operating margin is -40.45%. Annual revenue is $944M.